BridgeBio Pharma, Inc.
BBIO
$66.54
$2.013.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -192.86M | -182.74M | -181.90M | -167.42M | -265.05M |
| Total Depreciation and Amortization | 1.44M | 1.40M | 1.32M | 1.28M | 1.37M |
| Total Amortization of Deferred Charges | 1.45M | 4.52M | -- | -- | 2.07M |
| Total Other Non-Cash Items | 83.95M | 71.19M | 80.48M | 83.07M | 53.35M |
| Change in Net Operating Assets | 49.61M | -3.93M | 19.42M | -116.17M | 12.95M |
| Cash from Operations | -56.42M | -109.57M | -80.68M | -199.24M | -195.33M |
| Capital Expenditure | -33.00K | -470.00K | -594.00K | -- | -47.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | 0.00 |
| Other Investing Activities | -14.32M | 4.93M | -12.41M | -1.60M | -3.19M |
| Cash from Investing | -14.35M | 4.46M | -13.00M | -1.60M | -3.24M |
| Total Debt Issued | 0.00 | 0.00 | 300.00M | 575.00M | 500.00M |
| Total Debt Repaid | 0.00 | 0.00 | 0.00 | -459.00M | 0.00 |
| Issuance of Common Stock | 13.21M | 8.02M | 7.16M | 5.76M | 2.85M |
| Repurchase of Common Stock | -7.43M | -3.03M | -2.00M | -50.05M | -1.40M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.96M | -5.89M | -3.12M | -11.38M | -27.51M |
| Cash from Financing | -2.18M | -894.00K | 302.04M | 60.33M | 473.93M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -72.96M | -106.00M | 208.36M | -140.50M | 275.37M |